BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. Based in Jerusalem.
BrainsWay: net income sharply up (+53.7%), sales sharply up (+34.8%), operating income sharply up (+190.2%).
- Net income sharply upFirst nine months 2026
Net income: $7M, vs. $5M a year earlier, i.e. +53.7%.
- Sales sharply upFirst nine months 2026
Revenue: $51M, vs. $38M a year earlier, i.e. +34.8%.
- Operating income sharply upFirst nine months 2026
Operating income: $7M, vs. $2M a year earlier, i.e. +190.2%.
- Cash flow sharply downFirst nine months 2026
Operating cash flow: $14M, vs. $19M a year earlier, i.e. −27.3%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + 2026 year-to-date − same period a year earlier). Sector median: companies in the — group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 126 | 113 | 113 |
| Current assets | 81 | 83 | 84 |
| Non-current assets | 44 | 30 | 29 |
| Equity | 82 | 70 | 73 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 28 | 26 | 22 |
| Non-current liabilities | 16 | 17 | 18 |
| Revenue | 51 | 38 | 52 |
| Gross profit | 29 | 28 | 39 |
| Operating income | 7 | 2 | 4 |
| Pre-tax income | 7 | 5 | 8 |
| Net income | 7 | 5 | 8 |
| Net income (attributable to shareholders) | 7 | 5 | 8 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | 14 | 19 | 17 |
In millions of dollars. The "H1" columns cover the first six months of the year.
Calculated from these figures
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | 56.3% | 75.0% | 75.4% |
| Operating margin | 13.8% | 6.4% | 8.3% |
| Net margin | 14.2% | 12.5% | 14.5% |
| Current ratio (current assets / current liabilities) | 2,9 x | 3,2 x | 3,7 x |
| Equity / total assets | 65.3% | 62.0% | 64.6% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Source: official company profile (Yahoo Finance), summary. Website: www.brainsway.com
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).